Skip to content

Rayan K. Al Jurdi

4 papers in the library · 1,810 citations · publishing 2013-2019

Papers

Sort Most recent Most cited

Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression.

Contemporary clinical trials communications December 1, 2019 Brittany O'Brien, Charles E. Green, Rayan K. Al Jurdi et al. 10 citations

More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a potentially promising rapid-acting therapy for treatment-resistant depression (TRD). However, few...

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION

Depression and Anxiety March 25, 2014 Rebecca B Price, Dan V. Iosifescu, James W. Murrough et al. 342 citations

BACKGROUND: Preliminary evidence suggests intravenous ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide. In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit...

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

The International Journal of Neuropsychopharmacology October 8, 2013 Colin N. Haile, James W. Murrough, Dan V. Iosifescu et al. 251 citations

Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between individual patients. Brain-derived neurotrophic factor (BDNF) has been investigated as a biomarker of treatment response in depression and has been implicated in the mechanism of action of ketamine. We evaluated plasma BDNF and associations with...

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

American Journal of Psychiatry August 28, 2013 James W. Murrough, Dan V. Iosifescu, Lee C. Chang et al. 1,207 citations

OBJECTIVE: Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. METHOD: This was a...